The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), ...

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...

Chemical companies in the US and Europe began exiting the pharmaceutical industry in the mid-1990s, when the British firm ICI ...

Tanabe Pharma focuses on therapeutic areas such as immunology and inflammation, vaccines, diabetes, and central nervous ...

Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...

The U.S. investment company said Friday that it will buy Mitsubishi Tanabe Pharma for about 510 billion yen, equivalent to $3.37 billion.

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking ...